INBX - Inhibrx Biosciences Inc.
130.665
-0.785 -0.601%
Share volume: 379,225
Last Updated: 04-28-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.20%
PREVIOUS CLOSE
CHG
CHG%
$131.45
-0.78
-0.01%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-09-2024 | 08-13-2024 | 11-14-2024 | 03-17-2025 | 05-14-2025 | 11-13-2025 | 03-19-2026 | |
| Total revenue | 0.000 | 100.000 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 100.000 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| inf% | -100.00% | nan% | nan% | nan% | ||||
| Operating expenses | 73.825 M | 160.998 M | 46.797 M | 0.000 | 42.901 M | 33.812 M | 30.923 M | |
| Selling general and admin | 9.974 M | 93.366 M | 7.904 M | 0.000 | 6.024 M | 5.277 M | 5.574 M | |
| Research and development | 63.851 M | 67.632 M | 38.893 M | 0.000 | 36.877 M | 28.535 M | 25.349 M | |
| Total expenses | 73.825 M | 160.998 M | 46.797 M | 0.000 | 42.901 M | 33.812 M | 30.923 M | |
| 118.08% | -70.93% | -100.00% | -21.19% | -8.54% | ||||
| Operating income | -73.825 M | -160.898 M | -46.797 M | 0.000 | -42.901 M | -33.812 M | -30.923 M | |
| Ebit | -73.825 M | 1.861 B | -46.756 M | 0.000 | -42.951 M | -33.858 M | -30.962 M | |
| Pretax income | -78.710 M | 1.858 B | -43.864 M | 0.000 | -43.311 M | -35.256 M | -32.834 M | |
| -2,460.58% | -102.36% | -100.00% | -18.60% | -6.87% | ||||
| Income tax | 0.000 | 2.000 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | -78.710 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| 100.00% | ||||||||
| Net income | -78.710 M | 1.858 B | -43.864 M | 0.000 | -43.311 M | -35.256 M | -32.834 M | |
| 2,460.58% | -102.36% | 100.00% | 18.60% | 6.87% |